People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

2:29am IST
Change (% chg)

$1.81 (+3.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Novak, Rodger 

Dr. Rodger Novak, M.D., has been Chairman of the Board of Directors, President and Founder of CRISPR Therapeutics Ltd since December 21, 2017. He was President, Co-Founder, Director of the Company from December 1, 2017. He is an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria. In his most recent position, he was Global Head, Anti-Infectives Research & Development at Sanofi, where he was responsible for small molecule and biologics R&D, including early drug discovery and clinical development. Before that he was a founder of Nabriva Therapeutics and served as its Chief Operating Officer for almost six years. He started his pharmaceutical career at Sandoz (Novartis), where he was appointed as the deputy Head of the Antibiotic Research Institute. He received his M.D. from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the United States in 1994. He was a postdoctoral fellow at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute NYU Medical Center. During his academic career he authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell. He is co-inventor of five patents.

Basic Compensation

Total Annual Compensation, USD 474,666
Restricted Stock Award, USD 326,360
Long-Term Incentive Plans, USD --
All Other, USD 887,555
Fiscal Year Total, USD 1,688,580

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --